Today’s record-breaking French fine against three drugmakers drew on the experience of a related 2014 Italian fine and may face an equally arduous legal battle, the head of the French competition authority has said.
Roche, Novartis and Genentech can be expected to appeal the fines totaling 444 million euros ($523 million)